{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:52:33Z","timestamp":1779187953446,"version":"3.51.4"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.37880","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T16:31:48Z","timestamp":1614011508000},"page":"e2037880","source":"Crossref","is-referenced-by-count":8,"title":["Factors Associated With a Patient\u2019s Decision to Select a Cost-effective vs the Most Effective Therapy for Their Own Eye Disease"],"prefix":"10.1001","volume":"4","author":[{"given":"Danyal","family":"Malik","sequence":"first","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Cao","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaron Castillo","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshun","family":"Gao","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Qian","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Montaner","sequence":"additional","affiliation":[{"name":"Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore"},{"name":"Department of Pathology, School of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akrit","family":"Sodhi","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"issue":"2","key":"zoi201136r1","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A brief history of anti-VEGF for the treatment of ocular angiogenesis.","volume":"181","author":"Kim","year":"2012","journal-title":"Am J Pathol"},{"issue":"6","key":"zoi201136r2","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study.","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"zoi201136r3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1634\/theoncologist.9-suppl_1-2","article-title":"Vascular endothelial growth factor as a target for anticancer therapy.","volume":"9","author":"Ferrara","year":"2004","journal-title":"Oncologist"},{"issue":"4","key":"zoi201136r4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"20","key":"zoi201136r5","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration.","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi201136r6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/bjophthalmol-2018-312691","article-title":"Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.","volume":"103","author":"Low","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"zoi201136r7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022031","article-title":"Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.","volume":"9","author":"Pham","year":"2019","journal-title":"BMJ Open"},{"issue":"4","key":"zoi201136r8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS Registry.","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"issue":"20","key":"zoi201136r9","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"zoi201136r10","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.ajo.2011.08.045","article-title":"Vision health disparities in the United States by race\/ethnicity, education, and economic status: findings from two nationally representative surveys.","volume":"154","author":"Zhang","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"zoi201136r13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.psych.56.091103.070141","article-title":"Prosocial behavior: multilevel perspectives.","volume":"56","author":"Penner","year":"2005","journal-title":"Annu Rev Psychol"},{"issue":"2","key":"zoi201136r14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1017\/S0963180109990521","article-title":"Altruism in medicine: its definition, nature, and dilemmas.","volume":"19","author":"Steinberg","year":"2010","journal-title":"Camb Q Healthc Ethics"},{"issue":"6","key":"zoi201136r15","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/0963721413492764","article-title":"Intuitive prosociality.","volume":"22","author":"Zaki","year":"2013","journal-title":"Curr Dir Psychol Sci"},{"issue":"2","key":"zoi201136r16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.neuron.2015.06.031","article-title":"A neurocomputational model of altruistic choice and its implications.","volume":"87","author":"Hutcherson","year":"2015","journal-title":"Neuron"},{"issue":"10","key":"zoi201136r17","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice.","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med"},{"issue":"2","key":"zoi201136r18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1369-6513.2001.00137.x","article-title":"The ethics of evidence-based patient choice.","volume":"4","author":"Parker","year":"2001","journal-title":"Health Expect"},{"issue":"4","key":"zoi201136r19","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ophtha.2015.12.001","article-title":"Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment.","volume":"123","author":"Mueller","year":"2016","journal-title":"Ophthalmology"},{"key":"zoi201136r20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1745-6215-11-31","article-title":"Reasons for participating in randomised controlled trials: conditional altruism and considerations for self.","volume":"11","author":"McCann","year":"2010","journal-title":"Trials"},{"issue":"5","key":"zoi201136r21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/15265160600862395","article-title":"Altruistic discourse in the informed consent process for childhood cancer clinical trials.","volume":"6","author":"Simon","year":"2006","journal-title":"Am J Bioeth"},{"issue":"2","key":"zoi201136r22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191856","article-title":"Pharmaceutical companies and healthcare providers: going beyond the gift\u2014an explorative review.","volume":"13","author":"Latten","year":"2018","journal-title":"PLoS One"},{"key":"zoi201136r11","first-page":"103","volume-title":"Social Motivation","author":"Batson","year":"2011"},{"key":"zoi201136r12","volume-title":"The Social Psychology of Prosocial Behavior","author":"Dovidio","year":"2006"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2776710\/malik_2021_oi_201136_1613428945.18049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T16:31:55Z","timestamp":1614011515000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2776710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37880","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]}}}